New ovarian cancer combo shows promise in early trial
NCT ID NCT05952453
First seen Mar 13, 2026 · Last updated May 08, 2026 · Updated 11 times
Summary
This study tests a three-drug chemotherapy and immunotherapy combination given before surgery, followed by maintenance therapy after surgery, in 20 people with newly diagnosed stage III or IV ovarian cancer. The goal is to see if this approach delays cancer progression. Participants must be candidates for standard chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
O'Neal Comprehensive Cancer Center at UAB
RECRUITINGBirmingham, Alabama, 35294, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.